Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib Induction and Maintenance in Crohn's Disease
NCT02914561Phase 3Completed
- Sponsor
- Galapagos NV
- Start
- Oct 2016
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 41
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in Crohn's disease (11 arms), sponsored by Galapagos NV. Primary endpoints: Percentage of Participants Who Achieved Clinical Remission by Crohn's Disease Activity Index (CDAI) at 58 weeks and Percentage of Participants Who Achieved Endoscopic Response at 58 weeks. Started Oct 2016; status: completed.
02
Drugs
filgotinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02914561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914561.